Recent Press Releases

Celyad Announces Commercial License Agreement for C-Cure(R) in Greater China

Celyad Announces Commercial License Agreement for C-Cure(R) in Greater China All costs leading to market approval to be paid by local partner New agreement contains high double digit royalties and...

Adaptimmune Expands Trial of T-cell Therapy for Synovial Sarcoma and Achieves Clinical Milestones

PHILADELPHIA, and OXFORD, UK, Sept. 1, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (ADAP), ("Adaptimmune" or the "Company"), a clinical stage biopharmaceutical company...

Gilead's Investigational Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide (F/TAF) Meets Primary 48-Week Objective in Phase 3 Study

– F/TAF Currently Under Review for Marketing Approval by U.S. and European Regulatory Agencies – FOSTER CITY, Calif.--(BUSINESS WIRE)--Sep. 2, 2015-- Gilead Sciences, Inc. (NASDAQ:GILD)...

Novimmune and Baxalta ink international bispecific antibody collaboration

GENEVA, SWITZERLAND--(Marketwired - Sep 2, 2015) - Novimmune SA announced today that it has signed an international research collaboration agreement with Baxalta Incorporated (Baxalta) to develop...

Ascletis Secures US$35 Million Financing

SHANGHAI, Sept. 2, 2015 /PRNewswire/ -- Ascletis announced today the completion of a US$35 million (RMB 220 million) financing. The investment was led by C-Bridge Capital, joined by Tasly...

Sangamo and Shire Restructure Collaboration to Accelerate Development of ZFP Therapeutics® for the Treatment of Hemophilia and Huntington's Disease

RICHMOND, Calif., Sept. 2, 2015 /PRNewswire/ -- Sangamo BioSciences, Inc. (SGMO), a leader in therapeutic genome editing, announced today that the company and its collaborator, Shire plc (LSE: SHP,...

Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide

THOUSAND OAKS, Calif. and BRUSSELS /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced top-line results from the STRUCTURE trial (STudy evaluating effect of RomosozUmab...

Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs

Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs Global Co-Development and Co-Commercialization Agreement in Alzheimer's Disease With...

Ardelyx Regains NaP2b Program from Sanofi

FREMONT, Calif., Sept. 1, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that...

Navitor Pharmaceuticals Appoints David M. Madden to Board of Directors and Michael N. Hall, PhD, to Scientific Advisory Board

Navitor Pharmaceuticals Appoints David M. Madden to Board of Directors and Michael N. Hall, PhD, to Scientific Advisory Board September 01, 2015 08:30 AM Eastern Daylight Time CAMBRIDGE, Mass.--(...

Trevena Announces Positive Results from Phase 2b Study of TRV130 in Acute Postoperative Pain

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc. (TRVN), a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors...

Audentes Therapeutics Acquires Cardiac Gene Therapy Company Cardiogen Sciences

Audentes Therapeutics Acquires Cardiac Gene Therapy Company Cardiogen Sciences Audentes Expands Portfolio to Include AAV Gene Therapy for Rare, Genetic Cardiac Diseases including CASQ2-CPVT, an...

GenomOncology appoints Dr. Benjamin Salisbury as Vice President, New Products and Marketing

GenomOncology appoints Dr. Benjamin Salisbury as Vice President, New Products and Marketing CLEVELAND, Sept. 1, 2015 /PRNewswire/ -- GenomOncology today announced that Benjamin Salisbury, Ph.D., has...

European Commission Grants Marketing Authorization for Kanuma™ (sebelipase alfa) for the Treatment of Patients of All Ages with Lysosomal Acid Lipase Deficiency (LAL-D)

CHESHIRE, Conn.--()--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the European Commission (EC) has approved Kanuma™ (sebelipase alfa) for long-term enzyme...

European Commission Grants Marketing Authorization for Strensiq™ (asfotase alfa) for the Treatment of Patients with Pediatric-Onset Hypophosphatasia (HPP)

CHESHIRE, Conn.--()--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that the European Commission has approved Strensiq™ (asfotase alfa) for long-term enzyme...

Valeant And AstraZeneca To Partner On Brodalumab

Valeant And AstraZeneca To Partner On Brodalumab 09/01/2015 US and EU regulatory submission planned in moderate-to-severe psoriasis in Q4 2015 LAVAL, Quebec, Sept. 1, 2015 /PRNewswire/ -- Valeant...

Intellia Therapeutics Secures $70 Million in Series B Financing

Intellia Therapeutics Secures $70 Million in Series B Financing -- Funds to Accelerate Discovery and Development of Curative Products Based on CRISPR/Cas9 Gene-Editing Technology -- -- Pipeline...

Bristol-Myers Squibb and QIMR Berghofer Medical Research Institute Announce Worldwide Collaboration to Discover Novel Immuno-Oncology Antibodies

NEW YORK & QUEENSLAND, Australia--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and QIMR Berghofer Medical Research Institute have signed a research collaboration and license...

Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant

WOODCLIFF LAKE, N.J. and STAMFORD, Conn., Aug. 31, 2015 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma L.P. announced today that they have...